Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Indication
3.2. Snippet by Treatment
3.3. Snippet by End Users
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing prevalence of benign prostatic hyperplasia
4.1.2. Restraints
4.1.2.1. Adverse Effects of Treatments
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
5.5. Regulatory Analysis
5.6. SWOT Analysis
5.7. Unmet Needs
6. By Indication
6.1. Introduction
6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Indication
6.1.2. Market Attractiveness Index, By Indication
6.2. Prostate Cancer*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Benign Prostatic Hyperplasia (BPH)
6.4. Prostatitis
7. By Treatment
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
7.1.2. Market Attractiveness Index, By Treatment
7.2. Radiation Therapy*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Chemotherapy
7.4. Immunotherapy
7.5. Hormone Therapy
7.6. Targeted Drug Therapy
7.7. Others
8. By End Users
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
8.1.2. Market Attractiveness Index, By End Users
8.2. Hospitals*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Oncology Centers
8.4. Ambulatory Surgical Centers
8.5. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. U.K.
9.3.6.3. France
9.3.6.4. Spain
9.3.6.5. Italy
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
Key Market Players
11.1. Novartis AG*
11.1.1. Company Overview
11.1.2. Product Portfolio
11.1.2.1. Product Description
11.1.2.2. Product Key Performance Indicators (KPIs)
11.1.2.3. Historic and Forecasted Product Sales
11.1.2.4. Product Sales Volume
11.1.3. Financial Overview
11.1.3.1. Company Revenue’s
11.1.3.2. Geographical Revenue Shares
11.1.3.3. Revenue Forecasts
11.1.4. Key Developments
11.1.4.1. Mergers & Acquisitions
11.1.4.2. Key Product Development Activities
11.1.4.3. Regulatory Approvals etc.
11.1.5. SWOT Analysis
11.2. GSK plc.
11.3. Astellas Pharma Inc.
11.4. Merck & Co., Inc.
11.5. JOHNSON & JOHNSON SERVICES, INC.
11.6. Pfizer Inc.
11.7. Sanofi SA
11.8. Bayer
11.9. Zydus Lifesciences Limited
11.10. Wellona Pharma
* Similar data will be provided for each market player.
Emerging Market Players
11.11. Candel Therapeutics, Inc.*
11.11.1. Pipeline Products Description
11.11.2. Product Key Performance Indicators (KPIs)
11.11.3. Key Activities
11.11.4. Market Entry Timelines
11.11.5. Product Penetration Rate
11.11.6. Sales Estimation and Projections
11.12. Essa Pharma
* Similar data will be provided for each market player.
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us